[VP-16 and VM-26 plus platinum drugs combined with radiotherapy in the treatment of small cell lung cancer].
OBJECTIVE
To compare the clinical efficacy of VP-16(etoposide) with VM-26(teniposide) both plus platinum drugs combined with radiotherapy in the treatment of patients with small cell lung cancer(SCLC).


METHODS
Seventy-four cases of SCLC were studied retrospectively. Forty-three patients were treated with VP-16 + DDP + CTX or VP-16 + DDP, the other 31 patients were treated with VM-26 + DDP or VM-26 + Carboplatin. The treatment of both groups was combined with radiotherapy.


RESULTS
There was no significant difference between VP-16 and VM-26 groups in response rate, 2-year-survival rate, and brain metastasis rate. But the blood toxicity was more serious in VM-26 group than in VP-16 group; 3-4 stage toxicity rate was 58.06% versus 27.91%.


CONCLUSIONS
The results indicate that both VP-16 and VM-26 combined with platinum drugs were effective chemotherapy protocols. The authors suggest choosing VP-16 protocols as the first choice for previously untreated SCLC patients.
Zeng
P
P
Department of Radiotherapy, Xiangya Hospital, Hunan Medical University, Changsha.
Yin
L
L
Luo
B
B
Liu
Z
Z
Jin
X
X
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013713:Teniposide / Q000008:administration & dosage
D003037:Cobalt Radioisotopes; D005047:Etoposide; D013713:Teniposide; D016190:Carboplatin; D002945:Cisplatin